

**Date and Time:** 26th September 2011 10:30-16:30

**Minutes:** Confirmed

**Hepatitis B GDG Meeting 1**

**Place:** NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ

**Present:** GDG

1. Howard Thomas (Chair)	HT
2. Elizabeth Boxall	EB
3. Javier Vilar	JV
4. Angela Narbey	AN
5. Geoffrey Dusheiko	GD
6. Aftab Ala	AA
7. Emily Lam	EL
8. Steven Bradley	SB

NCGC Technical team

9. Gill Ritchie	GR
10. Grammati Sarri	GS
11. Rosa Lau	RL
12. Laura Sawyer	LS
13. Amy Kelsey	AK
14. Richard Whittome	RW
15. Jaymeeni Solanki	JS

NICE

16. Sarah Dunsdon	SD
-------------------	----

Observers

17. Nadia Permalloo – present for notes 1-8	NP
18. Lola Adedokun - present for notes 6-8	LA

Apologies

19. Alan Mitchell	AM
20. Sarah Chalmers	SC
21. Gareth Tudor-Williams	GTW

## Notes

1. The Chair welcomed the group to the Hepatitis B Guideline Development Group (GDG) meeting 1 and asked members to introduce themselves.
2. The Chair asked the GDG to declare if they had any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare.

EB declared a personal pecuniary interest: she was involved in a consulting arrangement with Sanofi Pasteur with regard to Hepatitis B vaccine in babies. She was also paid to attend a focus group on antiviral drugs lead by Gilead which consisted of presentations on epidemiology, current pathways and EASL guidelines.

GD declared a personal pecuniary interest: he has served as an advisor to and received consulting fees from Abbott, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Human Genome Sciences, Novartis, Pharmasset, Pfizer, Roche/Genentech, Schering-Plough/Merck, Tibotec, Vertex Pharmaceuticals and Zymogenetics. He has received travel support from Gilead Science and Schering-Plough/Merck and grant support from Gilead Sciences, Novartis, Pharmasset, Roche/Genentech, Schering-Plough/Merck, Tibotec and Vertex Pharmaceuticals. He also declared a personal family interest: his wife holds approximately \$2,500 worth of MSD stock. These have been held since 2000 and no trading in these shares has occurred.

EL declared a personal non-pecuniary interest: she has been a community member on the NICE Hepatitis B and C Testing Programme Development Group since March 2011.

HT declared a personal pecuniary interest: he is Chairman of Imperial College spin-out company which is not involved in Hepatitis B. He also lectured on Hepatitis C at ID meeting in Berlin in 2011, the expenses and honorarium were paid by industrial sponsor.

JV declared a non-personal pecuniary interest: Gilead have agreed to support and audit in his unit into Hepatitis B. The sponsorship is to support a part time data collecting clerk (under £3000). Also, Roche have supported through an unrestricted grant a Hepatitis C study (investigator initiated) in his department. JV is the principle investigator but receives no personal payment in the study.

SB had no interests to declare.

The NCGC technical team had no interests to declare.

No actions were taken following these declarations and none of the GDG members withdrew as this was an introductory meeting and therefore no evidence or recommendations were to be discussed.

3. The Chair then briefed the group on the meetings objectives.
4. The Chair introduced Amy Kelsey, NCGC Project Manager, who gave a presentation introducing the NCGC and the Guideline Development Process.
5. The Chair introduced Sarah Dunsdon, NICE Guidelines Commissioning Manager, who gave a presentation on NICE, clinical guidelines and quality standards and took questions from the group.
6. SD then gave a presentation on Patient and Carer Involvement to the group on behalf of Sarah Chalmers, NICE Patient and Public Involvement Project Manager.
7. The Chair introduced Gill Ritchie, NCGC Operations Director and Guideline Lead for Hepatitis B, who gave a presentation on declarations of interest and took questions from the group.

## Notes

8. The Chair introduced Richard Whittome, NCGC Information Scientist, who gave a presentation to the group detailing the role of the Information Scientist in guideline development. RW then took questions from the group.
9. The Chair introduced Grammati Sarri, NCGC Senior Research Fellow, who gave a presentation on Guidelines, Decision making and GRADE. GS then took questions from the group.
10. The Chair introduced Laura Sawyer, NCGC Senior Health Economist, who gave a presentation on using health economic evidence and guideline development. LS then took questions from the group.
11. The Chair presented the outline of the scope to the GDG and took questions from the group.
12. GR presented an update of the Hepatitis B Health Technology Appraisals and how they will be incorporated into the Hepatitis B clinical guideline and quality standard. The GDG agreed to the proposal. GR will update the GDG at the next meeting.
13. GS and Rosa Lau then led discussion with the GDG on the research protocols for 3 clinical questions. The pharmacological research protocols were agreed and signed off by the group:
14. The Chair introduced Jaymeeni Solanki, NCGC Project Coordinator who gave a short introduction to Claramentis, a web-based intranet site for document sharing, version control and forums.
15. There was no other business to discuss. The Chair closed the meeting and thanked everyone for attending.

## Date, time and venue of the next meeting

16. Tuesday 1<sup>st</sup> November 2011, 10:30-16:30, NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ.